Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
2006 ◽
Vol 17
(5)
◽
pp. 587-595
◽
2004 ◽
Vol 27
(5)
◽
pp. 441-446
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 753-753
◽
2002 ◽
Vol 3
(3)
◽
pp. 183-184
◽
2006 ◽
Vol 29
(3)
◽
pp. 267-275
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 704-704
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 704-704
2009 ◽
Vol 32
(1-2)
◽
pp. 18-24
◽
2011 ◽
Vol 47
(14)
◽
pp. 2091-2098
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 818-818